| Andexxa |
125586 |
002 |
351(a) |
Coagulation Factor Xa (Recombinant), Inactivated-zhzo |
Injection |
Intravenous |
200MG |
Single-Dose Vial |
2018/12/31
|
AstraZeneca AB |
Rx |
Licensed |
|
N/A |
| Vaxelis |
125563 |
001 |
351(a) |
Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine |
Injection |
Intramuscular |
0.5ML |
Single-Dose Vial |
2018/12/21
|
MSP Vaccine Company |
Rx |
Licensed |
|
N/A |
| Ultomiris |
761108 |
001 |
351(a) |
ravulizumab-cwvz |
Injection |
Intravenous |
300MG/30ML (10MG/ML) |
Single-Dose Vial |
2018/12/21
|
Alexion Pharmaceuticals, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Elzonris |
761116 |
001 |
351(a) |
tagraxofusp-erzs |
Injection |
Intravenous |
1,000MCG/1ML |
Single-Dose Vial |
2018/12/21
|
Stemline Therapeutics, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Asparlas |
761102 |
001 |
351(a) |
calaspargase pegol-mknl |
Injection |
Intravenous |
3,750UNITS/5ML (750UNITS/ML) |
Single-Dose Vial |
2018/12/20
|
Servier Pharmaceuticals LLC |
Rx |
Licensed |
N/A |
N/A |
| Herzuma |
761091 |
001 |
351(k) Biosimilar |
trastuzumab-pkrb |
For Injection |
Intravenous |
420MG |
Multi-Dose Vial |
2018/12/14
|
CELLTRION, Inc. |
Rx |
Licensed |
trastuzumab |
Herceptin |
| Cutaquig |
125668 |
001 |
351(a) |
Immune Globulin Subcutaneous (Human)-hipp |
Solution |
Subcutaneous |
1.65G/10 ML |
Single-Dose Vial |
2018/12/12
|
Octapharma Pharmazeutika Produktionsges.m.b.H. |
Rx |
Licensed |
|
N/A |
| Cutaquig |
125668 |
002 |
351(a) |
Immune Globulin Subcutaneous (Human)-hipp |
Solution |
Subcutaneous |
3.3G/20 ML |
Single-Dose Vial |
2018/12/12
|
Octapharma Pharmazeutika Produktionsges.m.b.H. |
Rx |
Licensed |
|
N/A |
| Cutaquig |
125668 |
003 |
351(a) |
Immune Globulin Subcutaneous (Human)-hipp |
Solution |
Subcutaneous |
1G/6ML |
Vial |
2018/12/12
|
Octapharma Pharmazeutika Produktionsges.m.b.H. |
Rx |
Licensed |
|
N/A |
| Cutaquig |
125668 |
004 |
351(a) |
Immune Globulin Subcutaneous (Human)-hipp |
Solution |
Subcutaneous |
2G/12ML |
Single-Dose Vial |
2018/12/12
|
Octapharma Pharmazeutika Produktionsges.m.b.H. |
Rx |
Licensed |
|
N/A |
| Cutaquig |
125668 |
005 |
351(a) |
Immune Globulin Subcutaneous (Human)-hipp |
Solution |
Subcutaneous |
8G/48ML |
Single-Dose Vial |
2018/12/12
|
Octapharma Pharmazeutika Produktionsges.m.b.H. |
Rx |
Licensed |
|
N/A |
| Cutaquig |
125668 |
006 |
351(a) |
Immune Globulin Subcutaneous (Human)-hipp |
Solution |
Subcutaneous |
4G/24ML |
Single-Dose Vial |
2018/12/12
|
Octapharma Pharmazeutika Produktionsges.m.b.H. |
Rx |
Licensed |
|
N/A |
| Truxima |
761088 |
001 |
351(k) Biosimilar |
rituximab-abbs |
Injection |
Intravenous |
100MG/10ML (10MG/ML) |
Single-Dose Vial |
2018/11/28
|
CELLTRION, Inc. |
Rx |
Licensed |
rituximab |
Rituxan |
| Truxima |
761088 |
002 |
351(k) Biosimilar |
rituximab-abbs |
Injection |
Intravenous |
500MG/50ML (10MG/ML) |
Single-Dose Vial |
2018/11/28
|
CELLTRION, Inc. |
Rx |
Licensed |
rituximab |
Rituxan |
| Tresiba |
203314 |
003 |
351(a) |
insulin degludec |
Injection |
Subcutaneous |
1,000UNITS/10ML (100UNITS/ML) |
Multi-Dose Vial |
2018/11/21
|
Novo Nordisk Inc. |
Rx |
Licensed |
N/A |
N/A |
| Gamifant |
761107 |
001 |
351(a) |
emapalumab-lzsg |
Injection |
Intravenous |
10MG/2ML (5MG/ML) |
Single-Dose Vial |
2018/11/20
|
Swedish Orphan Biovitrum AB (publ) |
Rx |
Licensed |
N/A |
N/A |
| Gamifant |
761107 |
002 |
351(a) |
emapalumab-lzsg |
Injection |
Intravenous |
50MG/10ML (5MG/ML) |
Single-Dose Vial |
2018/11/20
|
Swedish Orphan Biovitrum AB (publ) |
Rx |
Licensed |
N/A |
N/A |
| Actemra |
125472 |
002 |
351(a) |
tocilizumab |
Injection |
Subcutaneous |
162MG/0.9ML |
Autoinjector |
2018/11/19
|
Genentech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Udenyca |
761039 |
001 |
351(k) Biosimilar |
pegfilgrastim-cbqv |
Injection |
Subcutaneous |
6MG/0.6ML |
Pre-Filled Syringe |
2018/11/02
|
Accord BioPharma Inc. |
Rx |
Licensed |
pegfilgrastim |
Neulasta |
| Hyrimoz |
761071 |
001 |
351(k) Interchangeable |
adalimumab-adaz |
Injection |
Subcutaneous |
40MG/0.8ML |
Pre-Filled Syringe |
2018/10/30
|
Sandoz Inc. |
Rx |
Licensed |
adalimumab |
Humira |